Novo Nordisk to advance subcutaneous and oral amycretin for weight management into phase 3 clinical development
The decision to advance subcutaneous and oral amycretin into phase 3 is based on feedback received from regulatory authorities
The decision to advance subcutaneous and oral amycretin into phase 3 is based on feedback received from regulatory authorities
The trial tested six injectable doses and three oral doses over as long as 36 weeks
Subscribe To Our Newsletter & Stay Updated